oasis 1 semaglutide ADA Clinical Trial Talks: Oral for Treatment of Obesity and Type 2 Diabetes Investigators present findings from OASIS

Committee recommendations, while non-binding, heavily influence FDA decisions

Lancet Microbe 2 , e60e69 (2021)

1 This article explores how in-depth analytics can provide greater insight into the treatment journey for patients using GLP-1s

By activating FAK, it promotes the formation and turnover of focal adhesions, which are essential for cell migration, proliferation, and survival

This hormone plays a crucial role in managing blood sugar levels and body weight

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes